A new cause for CA 19.9 elevation: Heavy tea consumption [2]

Gut

Volumn 52, Issue 6, 2003, Pages 913-914

  Howaizi, M ^a,b   Abboura, M ^a   Krespine, C ^b   Sbai Idrissi, M S ^b   Marty, O ^c   Djabbari Sobhani, M ^b  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b Groupement Hosp Eaubonne M   (France)

^c Centre d'Exploration de l'Appareil Digestif   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; FLAVONOID; TUMOR MARKER;

ADULT; BLOOD LEVEL; CASE REPORT; CHOLESTASIS; DIAGNOSTIC IMAGING; FEMALE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HUMAN; LABORATORY TEST; LETTER; OBSTRUCTIVE JAUNDICE; PRIORITY JOURNAL; TEA; BLOOD; LABORATORY DIAGNOSIS; MIDDLE AGED;

CA-19-9 ANTIGEN; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MIDDLE AGED; TEA; TUMOR MARKERS, BIOLOGICAL;

EID: 0038522808     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.6.913     Document Type: Letter

References (18)

1. Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol 1999;10(suppl 4):145-9.
2. Mann DV, Edwards R, Ho S, et al. Elevated tumour marker CA19.9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000;26:474-9.
3. von Ritter C, Eder MI, Stieber P, et al. Biliary mucin secreted by cultured human gallbladder epithelial cells carries the epitope of CA 19-9. Anticancer Res 1997;17:2931-4.
4. Maestranzi S, Przemioslo R, Mitchell H, et al. The effect of benign and malignant liver disease on the tumour markers CA19.9 and CEA. Ann Clin Biochem 1998;35:99-103.
5. Halme L, Karkkainen P, Isoniemi H, et al. Carbohydrate 19-9 antigen as a marker of non-malignant hepatocytic ductular transformation in patients with acute liver failure. A comparison with alpha-fetoprotein and carcinoembryonic antigen. Scand J Gastroenterol 1999;34:426-31.
6. de Goede E, Yap SH. An exceptional high concentration of serum CA 19.9 in a patient with alcoholic liver disease. Gut 1997;41:579-80.
7. Wiseman S, Mulder T, Rietveld A. Tea flavonoids: bioavailability in vivo and effects on cell signaling pathways in vitro. Antioxid Redox Signal 2001;3:1009-21.
8. Pines E, Slama JL, Holeman A, et al. Unusually high CA19.9 in chronic pancreatitis. Gastroenterol Clin Biol 1995;19:641-2.
9. Safi F, Roscher R, Beger HG. The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma. Bull Cancer 1990;77:83-91.
10. Petit JM, Vaillant G, Olsson NO, et al. Elevated serum CA19.9 levels in poorly controlled diabetic patients. Relationship with Lewis blood group. Gastroenterol Clin Biol 1994;18:17-20.
11. Mukae H, Hirota M, Kohno S, et al. Elevation of tumor-associated carbohydrate antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993;148:744-51.
12. Cantagrel A, Moulinier L, Beljio K, et al. Increase of CA 19-9 in dysimmune inflammatory rheumatism. Apropos of 6 cases. Rev Rhum Ed Fr 1994;61:599-606.
13. Inayama Y, Uesato M, Takase K, et al. Immunohistochemical study of CA 19-9 and SPan-1 in cases of hydronephrosis. Urol Int 1996;57:93-8.
14. Harada T, Kubota T, Aso T. Usefulness of CA19.9 versus CA125 for the diagnosis of endometriosis. Fertil Steril 2002;78:733-9.
15. Matsubayashi H, Kuraoka K, Kobayashi Y, et al. Ruptured epidermoid cyst and haematoma of spleen: a diagnostic clue of high levels of serum carcinoembryonic antigen, carbohydrate antigen 19-9 and sialyl Lewis x. Dig Liver Dis 2001;33:595-9.
16. Ott K, Sendler A, Heidecke CD, et al. Bronchogenic cyst of the esophagus with high tumor marker levels a case report and review of the literature. Dis Esophagus 1998;11:130-3.
17. Nakamura T, Maruyama K, Kashiwabara H, et al. Diverticulitis causing a high serum level of carbohydrate antigen 19-9: report of a case. Surg Today 2002;32:282-4.
18. Tekin O. Hypothyroidism-related CA 19.9 elevation. Mayo Clin Proc 2002;77:398.